A recent study has concluded that the “novel” technique of serration angioplasty with the Serranator balloon (Cagent Vascular) for the treatment of chronic limb-threatening ischaemia (CLTI) in the pedal arteries is “safe and effective”. Following his presentation of this key finding at the 2023 Charing Cross (CX) International Symposium (25–27 April, London, UK), investigator Edward Gifford (Hartford, USA) sat down with Peter Schneider (San Francisco, USA) in the CX Vascular Live studio to discuss not only the study outcomes but also how serration technology disrupts the treatment landscape in this challenging patient population.
Gifford began by describing CLTI in the pedal arteries as a “really complex problem” and underscored the fact that there are limited treatment options available. Against this backdrop, Gifford explained that in a retrospective study—incorporating data from the USA and Germany—he and his team recorded “favourable” results using serration angioplasty with the Serranator balloon in vessels below the ankle joint.
Considering the broader topic area, Schneider posed questions about what makes Serranator different from other modified balloons available for use in the pedal arteries, and how the balloon addresses common safety concerns associated with treatment in these vessels. This is an anatomy in which on-table vessel injury can be “catastrophic” for the patient, Gifford suggested. The difficulties of treating patients with CLTI were also a topic of discussion, with Gifford noting that alongside an efficacious treatment outcome there needs to be durability—something that Gifford pointed out the Serranator appears to offer.
This video is sponsored by Cagent Vascular.
